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“Il y a plus de vieux ivrognes que de vieux médecins” 
- François Rabelais 
  
  
  
ABSTRACT 
Despite advances in diagnostics and treatments, many cancer patients have poor survival 
rates. Tumours develop drug resistance followed by metastasis, and survivors suffer from 
treatment side-effects. Omics techniques, targeted treatments and immunotherapy offer the 
prospect of individually adapting treatments for optimal efficacy and minimal side-effects. 
This requires integration of biomolecular, clinical and drug data to successfully predict 
optimal treatments for every patient. The aim of this thesis was to evaluate and apply 
different methodologies important for personalised treatment in a variety of cancer settings. 
The first paper showed that E6/E7 mRNA detection through RT-NASBA is more accurate 
and sensitive than DNA genotyping for classifying HPV infection in cervical 
adenocarcinoma, showing RNA analysis to be preferable for identifying high-risk patients. 
In paper II, HPV16 E2 and E5 mRNA expression in oropharyngeal cancer was analysed in 
relation to clinical outcomes and tumour immunology. Neither down-regulation of HLA 
class I nor CD8
+
 T-cell infiltration, both indicators of good prognosis, were dependent on 
E2 or E5. However, absence of E2 was related to poor progression-free survival. This 
allows E2 expression to be combined with HLA class I and CD8
+
 T-cells when stratifying 
patients with good prognosis for milder treatment. 
The third paper screened combinations of growth factors and drugs for impact on 
proliferation of breast cancer cells, creating a two-dimensional space to simulate tumours in 
different signalling states interacting with drugs. In MDA-MB-231 cells, TGF-β in 
combination with EGF and oestrogen inhibited growth, with the effect strengthened by 
Tamoxifen. In MCF7 cells, Tamoxifen inhibited growth when added to both EGF and 
oestrogen.  
In paper IV, the immunoproteome in urinary bladder cancer was analysed. Proteomics and 
network analysis of regulatory (Treg) and effector T-cells (Teff) of lymph nodes showed 
that Tregs in sentinel nodes (SN) up-regulate growth and immune signalling networks. IL-
16, previously not shown to be expressed by Tregs, was predicted as central to SN-Treg 
signalling. IL-16 expression in Tregs was validated, shown to be higher in lymph nodes 
than peripheral blood and inhibited by tumour cell supernatant. 
In conclusion, this thesis has shown methods to improve patient stratification in cervical 
adenocarcinoma and HPV-positive oropharyngeal cancer. The utility of proliferation 
screenings replicating tumour heterogeneity for optimising drug combinations was 
demonstrated, and finally, lymph node proteomics revealed individual differences in T-cell 
signalling, important for optimising immunotherapy. Integration of these and other methods 
will be key to arrive at personalised cancer medicine – application of the optimal treatment 
combination for every patient. 
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1 INTRODUCTION 
Despite more than a century of developments in cancer research, the global burden of 
cancer is still very high, with 14.1 million new cases and 8.2 million deaths worldwide in 
2012 [1] and projected to increase, both because of an ageing population and more people 
adopting a Western lifestyle [2]. Current treatments, relying heavily on surgery, radio- and 
chemotherapy, have not been able to turn this trend. Surgery, while often beneficial in 
earlier stages, is not curative in advanced cancer and radiotherapy is seldom effective 
against large tumour bulks. These treatments are rarely curative in late-stage, metastatic 
disease, which causes the great majority of cancer deaths [3]. While some kind of 
pharmacological treatment is often necessary, chemotherapy comes with heavy side-effects 
and resistance development.  
The cause of resistance development is the heterogeneous nature of tumours. Cancer is 
driven by genetic instability, allowing cells to acquire a wide range of random mutations, 
with clonal expansion of mutations providing a selective growth advantage [4]. Advanced 
cancers, consisting of many such clonal populations not only at sites of metastasis, but also 
within the primary tumour, are therefore resilient to external perturbations and may easily 
adapt to treatments which do not target this entire, genetically diverse, population of 
neoplastic sub-clones (Fig. 1) [5]. 
Recent advances in diagnostics, treatments and modelling have allowed a potential way to 
address the problem of heterogeneity in cancer. In diagnostics, omics-type approaches have 
allowed the characterisation of the global changes in gene and protein expression in single 
patients, tissues and even cells [6]. On the treatment side, the advent of small molecules 
specifically targeting defined receptors and pathways allows more effective treatments with 
fewer side effects for patients with tumours susceptible to these drugs [7]. The rapidly 
growing field of cancer immunotherapy is another approach to address heterogeneity and 
resistance development by harnessing the immune system to kill tumours. The immune 
system being a complex, adaptive system, has the ability to target a wide variety of cancer 
populations if immunosuppressive pathways induced by tumours can be repressed by drugs 
[8]. 
Systems biology approaches aim to make these advances useful in a clinical setting through 
integration of the growing amount of omics data with observed tumour phenotypes and 
clinical outcomes, modelling of perturbations in signalling pathways and predictions of 
drug effects. Integrating and modelling high-resolution patient data will allow the concept 
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of P4 - predictive, preventive, personalised and participatory – medicine, making sure that 
each single patient gets the right treatment targeting the right tumour at the right time [9].  
 
 
Figure 1. Tumour heterogeneity provides resilience to selective pressure caused by anti-
cancer drugs. Clonal expansion of resistant cells leads to multi-drug resistance. Reprinted 
by permission from Macmillan Publishers Ltd: Nature Biotechnology [10], copyright 2012. 
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This thesis has laid forward several methods facilitating personalised medicine in a variety 
of cancer settings – more precise diagnostics (paper I) and prediction of treatment response 
(paper II) in HPV-driven cancer, replicating tumour heterogeneity to study combinations of 
targeted therapies in breast cancer (paper III) and studying the immunoproteome on lymph 
node level to predict proteins which may be targeted to overcome immunosuppression in 
urinary bladder cancer (paper IV). 
 
1.1 CARCINOGENESIS 
Cancer development is a multi-step process, where cells acquire capabilities allowing them 
to proliferate uncontrollably and spread throughout the body while avoiding host defence 
mechanisms. A model of initiation, promotion and progression has been established, which 
starts with a cancer-initiating mutation event. This initiation, through changing the function 
or activity of a critical regulatory gene, makes a cell or population of cells (in the case of 
heritable cancer syndromes) susceptible to hyper-proliferation upon further aberrations, but 
does in itself not result in marked phenotypical changes. Tumour promotion is a non-
mutagenic, reversible event, causing clonal expansion of initiated cells, creating benign 
tumours. Progression introduces further genetic, irreversible changes into this expanded 
population, which becomes a malignant tumour consisting of aberrantly growing cells [11].  
Fearon and Vogelstein developed the classic model of multi-step carcinogenesis in colon 
cancer, showing that subsequent acquisitions of mutations in at least five genes are 
necessary for cells to be malignant [12, 13]. These are either proto-oncogenes, which, if up-
regulated through over-expression, mutation or translocation become oncogenes providing 
the tumour with capabilities of growth and metastasis, or tumour suppressors, which if 
down-regulated in the same manner remove intracellular checks against unlimited growth 
and dispersion. Figure 2 shows a general overview of the genetic changes during colon 
carcinogenesis. 
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Figure 2. Multi-step model of carcinogenesis in colon cancer. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Cancer [4], copyright 2003.  
 
Genetic changes in themselves do not cause cancer unless the mutated cells successfully 
transfer the mutation to daughter cells and there is a selective clonal expansion of cells 
carrying the mutation. Since the probability of a carcinogenic mutation in a specific allele is 
very low, development of a tumour requires a large clonal expansion of the initiated cell to 
make it probable that at least one cell in the expanded population acquires another 
carcinogenic mutation, with repeated mutations followed by further expansion until a 
cancerous state is reached [14]. However, this does not mean that the final tumour will 
consist of identical clones. Rather, the population expanded from the first initiated cell will 
undergo numerous mutation events. During this process, cells that acquire mutations 
rendering them relatively genetically unstable, but still viable, will not have a growth 
advantage, but a fitness advantage over other cells, since they as a population are more 
likely to survive diverse selective forces. At each stage in carcinogenesis, this will produce 
multiple sub-clones with different mutations that may provide a growth advantage under 
the right selective pressure, producing expanded populations of several, genetically 
different clones (Fig. 3) [15]. 
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Figure 3. Expansion of a genetically unstable population of pre-malignant cells creates 
different sub-clones, increasing the chance that the population as a whole can adapt to and 
bypass selection barriers. Reprinted from [15] with permission from Elsevier. 
 
1.2 CANCER SIGNALLING PATHWAYS 
During the process of carcinogenesis from an initiated cell to a heterogeneous, invasive 
tumour, a multitude of pathways in the cancer cells themselves, as well as in surrounding 
tissues, are de-regulated. The general characteristics of these de-regulated pathways have 
been summarised by Hanahan and Weinberg as the Hallmarks of Cancer [16]. These 
hallmarks are: sustained proliferative signalling, evasion of growth suppressors, apoptosis 
resistance, immortality, angiogenesis and metastasis. The acquisition of these hallmarks is 
promoted by genetic instability and tumour-promoting inflammation, both of which create a 
multitude of mutations in somatic cells, of which a small number acquire mutations in 
pathways of the described hallmarks, giving them advantages in the areas of growth, 
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survival and invasion. The authors also describe two emerging hallmarks of cancer cells – 
changes in energy metabolism and evading elimination by the immune system (Fig. 4).  
 
Figure 4. The hallmarks of cancer, with inhibitors targeting hallmark pathways. Reprinted 
from [16] with permission from Elsevier. 
 
Normally, cells receive signals to proliferate through soluble ligands binding to cell surface 
growth receptors which, through intracellular signalling pathways, transfer the signal to the 
nucleus. Examples are the EGF, IGF and VEGF signalling pathways which all cross-talk 
through downstream signalling pathways such as the mTOR pathway [17]. In cancer cells, 
sustained proliferative signalling can be achieved by different modes of up-regulated 
proliferation pathway signalling such as increased production of growth factors, increased 
number of growth receptors, constitutively active receptors or downstream pathway 
components, disruption of negative feedback loops or through cross-talk with the 
surrounding stroma [18, 19]. 
Contact inhibition, cell cycle checkpoints and DNA damage sensors all contribute to tightly 
regulated cell proliferation. The numerous checks on proliferation, integrating signals from 
cell-cell contact inhibition, extracellular inhibitory factors, DNA damage and oxidative 
stress to avoid a hyper-proliferative phenotype, push cells either into cell cycle arrest, 
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apoptosis or senescence when growth conditions are deemed suboptimal. Cancer cells de-
regulate these growth-regulatory pathways in a number of ways. The classic examples are 
mutation or (through MDM2 up-regulation) inactivation of the tumour suppressor p53 and 
inactivation of cell cycle inhibitor pRb through phosphorylation, allowing continued 
proliferation in the presence of DNA damage or extracellular inhibitory signals [20].  
Apoptosis is likewise avoided either by inactivation of p53 or up-regulation of anti-
apoptotic proteins [21], while the limit on the number of replicative cycles is broken 
through production of telomerase. This protein lengthens the telomeres, thus bypassing the 
Hayflick limit on replication [22]. 
Another hallmark is the capability to induce angiogenesis. Through production of 
angiogenic factors such as VEGF, FGF and PDGF, driven in part through the hypoxic 
tumour environment and HIF-1α signalling, formation of disorganised, leaky vessels with 
poor pericyte coverage and decreased perfusion in association to the tumour mass is 
induced [23].  
Cancer tissues are also metabolically reprogrammed, with many cells switching to aerobic 
glycolysis for generation of ATP through fermentation of pyruvate to lactate even when 
oxygen is available. This is achieved through up-regulation of GLUT1 glucose transporters 
and enzymes in the glycolytic pathway while pyruvate dehydrogenase is inhibited, 
decreasing import of substrate for the citric acid cycle. HIF-1α is a central regulator of this 
reprogramming [24]. Although this is far less efficient than oxidative phosphorylation, 
aerobic glycolysis has several advantages. Apart from allowing survival in a hypoxic 
environment, aerobic glycolysis intermediates are shunted into the pentose phosphate 
pathway, creating nucleic acid precursors, necessary for sustained proliferation, and 
NADPH, necessary for cells to survive oxidative stress [25]. Excretion of lactate fuels 
neighbour cancer cells that use oxidative phosphorylation, reflecting a metabolic 
heterogeneity [26], while the excretion of protons, aided by up-regulation of ion exchange 
proteins, creates an acidic extracellular environment which increases invasiveness and 
hypoxic signalling while contributing to immunosuppression and drug resistance [27, 28]. 
Distant metastasis, the main cause of death in cancer patients, is another hallmark pathway. 
Functionally, cancer cells detach from their neighbours, break down extracellular matrix, 
become motile and migrate across the basal membrane, enter  lymph and blood vessels, 
already remodelled through tumour-induced angiogenesis, and spread to distant organs 
where they intravasate and form new tumours [29]. To facilitate extravasation, successful 
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colonisation and growth of a metastasis from disseminated tumour cells, primary tumours 
secrete cytokines, growth factors and exosomes. These molecules signal a remodelling of 
distant tissues and recruit immune cells that are immunosuppressive and help remodel the 
tissue. This creates a pre-metastatic niche that is favourable to subsequent colonisation by 
disseminated tumour cells [30].  
On a molecular level, the gain of invasive capabilities is associated with a transformation of 
epithelial cancer cells to a more mesenchymal-like state (EMT), driven by TGF-β, Wnt and 
Notch signalling [31]. Аdhesion molecules such as E-cadherin are down-regulated while 
integrins, aiding motility, and matrix metalloproteinases, breaking down surrounding 
extracellular matrix, are up-regulated and cell polarity is lost through cytoskeletal 
rearrangements [32]. 
 
1.3 TUMOUR HETEROGENEITY 
Driving these pathway changes is genetic instability, which is seen in a multitude of cancers 
and is associated with worsened prognosis. This instability is the effect of defects in DNA 
repair and cell cycle checkpoint proteins and contributes to an increased mutation rate. A 
mutator phenotype is often seen in hereditary cancer syndromes, with defects in DNA 
repair proteins such as BRCA1 in breast and ovarian cancer or MSH2 in Lynch syndrome, 
but sporadic cancers also show high rates of genetic instability in the form of microsatellite 
instability and aneuploidy [33].  
Genetic instability creates a diverse population of tumour sub-clones, increasing the 
chances of overcoming barriers to proliferation and invasion through acquisition of 
mutations [34, 35] and of developing mechanisms of drug resistance [36, 37]. Although 
there is a degree of functional convergence between acquired genomic changes in different 
patients, relatively similar phenotypes can be achieved by point mutations at different sites, 
copy number alterations and epigenetic modifications of different genes, leading to the 
same cancer phenotype but with vastly different underlying genetic changes, making it 
difficult to apply one single treatment to large patient groups [38].  
Heterogeneity is not only seen between, but also within patients, called intra-tumour 
heterogeneity. Genetically and functionally distinct sub-clones of cancer cells can be seen 
at different sites of metastasis, reflecting adaptations during the metastatic process and to 
the metastatic niche, but also at different sites within the same primary tumour. These sub-
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clones are not only genetically, but also phenotypically different. Examples from 
glioblastoma [39] and renal cell carcinoma [40] show different transcriptomic profiles, 
suggesting different prognoses and drug responses in different biopsies from the same 
tumour. In addition to heterogeneity between the cancer cells, differences in tumour 
microenvironment add yet another layer of diversity [41]. Putting such a diverse population 
of clones under evolutionary pressure by applying treatments has a high chance of selecting 
resistant sub-clones for expansion, thus failing to eradicate the tumour [42]. 
 
1.4 THE IMMUNE SYSTEM AND CANCER 
The immune system is a double-edged sword in the cancer setting, reviewed by 
Grivennikov et al. [43] (Fig. 5). Aspirin has been found to lower the lifetime risk of cancer 
[44], and chronic inflammation is associated with a range of tumours, from colorectal 
cancer in IBD patients or hepatocellular carcinoma in chronic hepatitis patients to gastric 
cancer in patients infected with H.pylori and pulmonary cancers linked to inflammation 
caused by smoking and asbestosis. Inflammation contributes to mutagenesis both through 
direct production of reactive oxygen species (ROS) and through induction, by cytokines, of 
ROS production in epithelial cells. Cytokine signalling also activates NF-κB and STAT3 
signalling in tumour cells. These signalling pathways up-regulate a number of the cancer 
hallmarks, such as proliferation, angiogenesis and invasion (Fig. 6).  
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Figure 5. Balance between pro- and anti-tumorigenic roles of the immune system. 
Reprinted from [43] with permission from Elsevier. 
 
In addition to this role, immune cells which contribute to tumour progression are actively 
recruited to the cancer site by tumour cells themselves through cytokine and TGF-β 
signalling and the attraction of immune cells to the hypoxic, necrotic tumour core. Tumour-
associated macrophages (TAM) contribute to proliferation, angiogenesis and metastasis by 
production of growth factors and metalloproteases and tissue re-modelling. They have also 
been found to travel together with circulating tumour cells through the bloodstream. 
Myeloid-derived suppressor cells (MDSC) not only stimulate angiogenesis through VEGF 
production, but also limit elimination of the tumour by other immune cells such as NK cells 
and cytotoxic T-cells (CTL). Regulatory T-cells also have an immunosuppressive role, 
blocking CTL activation. 
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Figure 6. Tumour initiation (A) and promotion (B) through immune signalling. Reprinted 
from [43] with permission from Elsevier. 
 
However, these pro-tumorigenic roles of the immune system are counterbalanced by two 
anti-tumorigenic roles. Firstly, activation of the immune system by dying tumour cells is 
critical to the efficacy of conventional chemo- and radiotherapy [45]. Secondly, there is an 
immunosurveillance process where the immune system eliminates cancer cells throughout 
the carcinogenic process. Studies on immune-deprived mice show an increased incidence of 
spontaneous tumours and transplant patients undergoing immunosuppressive therapies 
show increased rates of non-pathogen-related cancers, in sites such as bladder, kidney and 
liver [46]. Furthermore, high numbers of tumour-infiltrating CTLs have been associated 
with good prognosis in many cancer types, including melanoma [47], bladder [48] and head 
and neck cancer [49].  
Mechanistically, early transformed cells are mainly eliminated by NK cells, recognising the 
early tumour as non-self, where after T-cells are primed by the dead cells and create a 
memory response against tumour antigens. However, the constant selective pressure of the 
immune system combined with the high rates of proliferation and mutation in cancer cells 
leads to a process of immunoediting, where cancer cells develop mechanisms to escape 
immune-mediated killing (Fig. 7)  [50]. 
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Figure 7. The process of immunoediting, where cancer tissues step-wise acquire 
capabilities allowing them to escape immune-mediated killing [50]. Copyright © 2007, 
John Wiley and Sons. 
 
1.4.1 Immunosuppressive Mechanisms 
Tumours can avoid immune destructions through two general mechanisms – either making 
themselves invisible to the immune system by down-regulating expression of tumour 
antigens and HLA class I molecules and up-regulating NK inhibitory ligands or by 
suppressing surrounding immune cells through recruitment of immunosuppressive cells and 
secretion of immunosuppressive molecules like TGF-β and IL-10. These mechanisms are 
reviewed by Vinay et al. [51]. Secretion of TGF-β by tumour cells and surrounding stroma 
directly inhibits CTLs and converts tumour-infiltrating CD4
+
 T-cells into Tregs. These T-
cells suppress the immune response through secretion of IL-10 and TGF-β, inhibition of 
Teff proliferation and cytokine release and inhibiting DC maturation [52]. Tumours also 
recruit, through chemoattractants, Tregs, MDSCs and TAMs. MDSCs suppress T-cells 
through down-regulation of the TCR ζ-chain, and TAMs produce TGF-β and IL-10, 
extending immunosuppression. These molecules inhibit DC maturation, producing 
immature, tolerogenic DCs.  
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Making themselves less visible and vulnerable to immune cells is achieved by cancer cells 
through down-regulating expression of MHC class I molecules and other components of the 
antigen-processing machinery, decreasing surface expression of antigens which may elicit 
an immune response. There is also death receptor down-regulation, making cancer cells less 
vulnerable to apoptosis by Fas-FasL interaction and up-regulation of ligands, such as PD-
L1, which inhibit immune cells upon contact. 
 
1.4.2 Immunotherapeutic Approaches 
Cancer immunotherapy seeks to harness the anti-cancer effects of the immune system as a 
way to efficiently fight the disease and create a long-term immune memory to prevent 
relapse through down-regulating immunosuppressive tumour signalling and stimulating 
immune-mediated elimination of cancer cells. 
To become activated, T-cells need two signals – binding of TCR to MHC class II peptide 
complex on APCs, guaranteeing a specific response against the antigen presented by the 
APC, and binding of CD28 to B7 on APCs, making sure that the antigen is presented by a 
dedicated APC. CTLA-4, expressed on T-cells, particularly Tregs, competitively binds B7, 
inhibiting the second signal and thus T-cell activation. Immune checkpoint blockade 
through antibodies targeting CTLA-4 restore T-cell activation and has been approved as 
melanoma treatment. Antibodies blocking PD-1 have also been approved as cancer 
treatment, while anti-PD-L1 antibodies are in clinical trials (Fig. 8) [53].  
Another immunotherapeutic approach is vaccination. A vaccine against prostate cancer, 
consisting of DCs cultured with the tumour antigen prostatic acid phosphatase, succeeded 
in increasing survival and was approved for treatment of prostate cancer [54]. Yet another 
approach, in trials, is chimeric antigen receptors (CAR). T-cells are engineered to express 
an extracellular tumour-antigen specific antibody linked to intracellular kinase signalling 
domains, creating T-cells which are constitutively active against tumour cells expressing 
the antigen [55].  
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Figure 8. Mechanisms of T-cell activation by immune checkpoint blockade antibodies. 
Reprinted from [56] with kind permission from Springer Science and Business Media. 
The graft-versus leukaemia effect, where donor bone marrow recognises host malignant 
host leukocytes as non-self, creating an immune reaction that eliminates the cancer is well 
established as a treatment for haematological malignancies [57]. Adoptive T-cell therapies 
use the same concept to target solid tumours [58]. TILs are separated from removed patient 
tumours, where after they are cultured with T-cell growth factors such as IL-2. T-cell 
clones shown to elicit a powerful immune response against tumour extract are then further 
expanded ex vivo and re-inserted into the patient as transfusion (Fig. 9).  
An advantage of this approach is that it is possible to adapt to mutations and relapse 
through repeating the process against the relapsed tumour. Notably, it has been shown that 
it is necessary to deplete the patient of Tregs for the treatment to be effective [59], and for 
clinical usage this type of therapy should optimally be combined with targeted treatments 
removing tumour tissue immunosuppression, increasing apoptosis and cancer cell antigen 
presentation [58]. 
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Figure 9. Adoptive T-cell transfer for cancer immunotherapy Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Immunology [60], copyright 2006. 
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1.5 HUMAN PAPILLOMAVIRUS  
A subset of cancers are transformed into malignant tumours through the action of HPV, 
which alone controls many of the pathways defined as hallmarks of cancer. HPV is an 
icosahedral double-stranded DNA virus in the Papillomaviridae family with tropism for 
squamous epithelia. In total, there are more than 170 different HPV types. Types 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58 and 59 are classified as high-risk (hrHPV) because of their 
carcinogenic potential. These are involved in the development of cervical, oropharyngeal 
and anogenital cancers. HPV16 and 18 are responsible for 50% and 20%, respectively, of 
cervical squamous cell carcinoma, while other hrHPV cause the remaining 30%. 
Oropharyngeal and anogenital squamous cell carcinomas, on the other hand, are mainly 
caused by HPV16 [61]. Apart from squamous cell carcinomas, HPV infection has also been 
linked to cervical adenocarcinoma [62]. 
The HPV genome is approximately 8 kb and encodes six early (E1, E2, E4, E5, E6, E7) and 
two late (L1, L2) proteins (Fig. 10). The genome also contains a long coding region (LCR), 
with elements regulating DNA replication and transcription [63].  
 
Figure 10. Organisation of the HPV genome. Reprinted from [63]. 
 
The HPV lifecycle starts with infection of proliferating cells in the basal layer of squamous 
epithelia. To reach the basal layer, breaks in the stratified epithelium are needed. Virions 
are internalised by clathrin-coated vesicles before unpacking inside the cell. In the basal 
layer, E1 and E2 keep episomal DNA separated from cellular DNA. As cells migrate to the 
supra-basal layer, expression of E6 and E7 pushes cells into S-phase, avoiding terminal 
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differentiation. These proliferating cells amplify the viral genome through the actions of 
E1, E2, E4 and E5. When the cells have reached the upper epithelial layers, L1 and L2 
genes are expressed, forming a capsid protein where genomes are packed. This is followed 
by shedding and re-infection [64]. 
Through its lifecycle, HPV deregulates several hallmarks of cancer. Circa 80% of HPV 
infections are transient and cleared by the immune system [65], and in total only 1% of 
women infected with hrHPV will develop invasive cervical cancer [66]. Avoidance of 
immune clearance is achieved through several methods. HPV E5 causes down-regulation of 
MHC class I CTL ligands HLA-A and B, but not HLA-C and D, which inhibit the Natural 
Killer (NK) cell response [67]. Both E6 and E7 inhibit interferon signalling, with E7 also 
repressing expression of MHC class I and APM components on promoter level [68, 69].  
The E6 and E7 proteins are most important for cell transformation. E6 causes ubiquitination 
of the tumour suppressor p53, leading to apoptosis resistance. It also induces expression of 
the telomerase hTERT, immortalising the infected cells. E7 removes the G1/S cell cycle 
checkpoint by binding pRB, releasing E2F to bind DNA and transcribe cell cycle genes, 
thus allowing continuous proliferation [70]. This has the side-effect of up-regulating cdk 
inhibitor p16, which is used as a surrogate marker of active HPV infection. E5, in addition 
to roles in immune escape and viral amplification, drives proliferation by increasing EGFR 
expression [71]. Chronic HPV infection may lead to integration of the viral genome into the 
host genome, giving the viral transcripts a longer half-life and disrupting E2 expression, 
which removes the suppressive effect of E2 on E6 and E7. In addition, genome integration 
causes genetic instability, favouring acquisition of the other hallmarks [72]. 
There are currently two approved prophylactic HPV vaccines, Gardasil directed against the 
L1-protein of HPV 6, 11, 16 and 18 and Cervarix against HPV16 and 18. However, 
vaccines targeting the L1 protein are not effective after cells have been infected by HPV. In 
addition, there is now also a nonavalent HPV vaccine, Gardasil 9, protecting against  6, 11, 
16, 18, 31, 33, 45, 52 and 58, that was approved by FDA in December 2014 [73]. In 
Sweden, subsidised HPV vaccination was available for girls ages 13-17 years old 2006-
2011. From 2012 onwards, HPV vaccination of girls ages 10-12 years was included as part 
of the national immunisation programme. Girls aged 13-18 years can also be vaccinated 
within а catch-up programme. 
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For cancerous or pre-cancerous lesions caused by HPV, immunotherapeutic strategies, 
targeting E6 and/or E7 are under development or in clinical trials, e.g. therapeutic peptide-
based vaccines [74] and adoptive T-cell transfer [75]. 
 
1.5.1 Cervical Cancer 
Worldwide, circa 500 000 women are diagnosed with cervical cancer annually, with the 
greater part being in developing countries, in many of which it is the leading cause of 
cancer death in women. 80% of cervical cancers are squamous cell carcinomas with the rest 
being adenocarcinomas; however, HPV is the causative agent in almost every case. Being 
HPV-driven, cervical cancer spreads through sexual activity, and risk factors include early 
sexual début, a high number of partners, immunosuppression and tobacco smoking [76].  
The standard screening test has traditionally been cervical cytology, Pap smear, which has 
around 90% specificity but can reach as low as 37% sensitivity. Recently, HPV testing has 
been introduced as an alternative or complement. HPV testing is more sensitive, with a 
sensitivity of around 90%, and was lately recommended as standard screening by WHO 
[77]. 
Cervical cancer develops from in-situ dysplasia, which is ranked from CIN1 (least atypical 
cells) to CIN3 (most atypical). These may develop into invasive carcinomas which 
metastasise locally to adjacent pelvic organs and lymph nodes before distant metastasis. 
Discovery of atypical cells or hrHPV on screening is followed by cervical biopsy and 
staging based on histology and invasion, which establishes the diagnosis. Five-year survival 
varies from 100% survival in microinvasive stage IA to 5-15% in distantly metastasised 
stage IV. Treatment options consist of radical hysterectomy with lymphadenectomy and 
radiotherapy in earlier stages and cisplatin-containing chemoradiotherapy in stages II and 
above [76]. Recently, the anti-VEGF antibody bevacizumab has also been approved for 
treatment of advanced stages [78]. 
 
1.5.2 Oropharyngeal Cancer 
Cancers of the oral cavity and oropharynx had an incidence of 400 000 with 223 000 deaths 
worldwide in 2008 [79]. Oropharyngeal squamous cell carcinomas (OSCC) can be divided 
into two clinically distinct subgroups – HPV-positive and HPV-negative. While risk factors 
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for the latter are mainly alcohol and smoking, the earlier is caused by HPV infection from 
sexual activity [80, 81]. In contrast to cervical cancer, where around 50% and 20% are 
attributed to HPV16 and HPV 18 respectively, close to 90% of HPV-positive OSCC are 
caused by HPV16, with HPV33 and 35 being the next most frequent types [82].  
HPV-positive OSCC is mainly found in the tonsils (TSCC) and base of tongue (BOTSCC), 
with an HPV prevalence in the County of Stockholm of 79% and 64%, respectively, for 
these sites [82], while less than 20% of OSCC outside these sites contain HPV DNA [83]. 
In the Western world, rates of HPV-negative OSCC/TSCC are declining, probably due to a 
decrease in smoking, while HPV-positive OSCC/TSCC has been on the rise since the 
seventies [82, 84, 85]. There is a clear difference in prognosis between the two types, with 
five-year survival rates around 80% in HPV-positive vs 40% in HPV-negative cancers with 
conventional surgery and radiotherapy [86, 87].  
HPV-positive OSCC are histologically less differentiated and show less keratinisation than 
HPV-negative OSCC. They also show much lower rates of p53 mutations, and have p16 
up- instead of down-regulated, when compared with HPV-negative OSCC. These 
differences are due to the impact of HPV on p53 degradation and pRb inactivation [88]. 
OSCC is most often discovered when patients get regional lymph node metastases. Before 
2008 treatment consisted mainly of conventional therapy and/or surgery. Thereafter, 
treatment has been intensified and now includes hyperfractionated radiotherapy, 
induction/concomitant chemotherapy and EGFR antibodies. In HPV-positive OSCC, 
several biomarkers have been found to be correlated to increased treatment response. E.g. 
patients with high numbers of CD8
+
 TILs or absence of MHC class I expression have 
survival rates of 95-100% with conventional radiotherapy alone [49, 89-91]. Many are thus 
over-treated, contributing to side-effects such as jawbone necrosis, difficulties swallowing 
and mouth dryness [87, 92]. By combining several biomarkers together with knowledge of 
tumour HPV status, OSCC patients can potentially be selected for less intensive treatment. 
 
1.6 BREAST CANCER 
Breast cancer is the most commonly diagnosed and leading cause of cancer death in women 
worldwide, with circa 1 700 000 cases and 500 000 deaths in 2012 [93]. Hormone 
replacement therapy, oral contraceptives, smoking, hysterectomy and diabetes mellitus 
increase breast cancer risk, while breastfeeding decreases it [94, 95]. There are also 
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hereditary risk factors, notably hereditary breast and ovarian cancer syndrome, caused by 
BRCA gene germline mutations [96]. 
Breast cancer is diagnosed using multiple modalities. MRI is recommended for younger 
women with a high risk of developing breast cancer. In the majority of cases, a finding on 
screening mammography (in Sweden starting at 40 years of age) is followed by diagnostic 
mammography, ultrasound and core needle biopsy. The biopsy is stained for oestrogen 
receptor (ER), progesterone receptor (PR) and HER2/neu expression and analysed by a 
pathologist.  
Tumours are classed based on histological grade, receptor status and TNM staging. Being a 
very heterogeneous disease, the prognosis depends on these parameters. Five-year survival 
for all women diagnosed is around 90%, but survival depends on stage and receptor status, 
with stage IV patients having below 20% five-year survival. Negative hormone receptor 
status and young age of onset (< 40 years old) are further negative prognostic factors [97, 
98]. 
The most common subtypes of breast cancer are invasive ductal carcinoma (80% of cases) 
and invasive lobular carcinoma (10%) [99]. At least 18 different histological types exist. 
Based on gene expression data, these can be grouped into seven molecular subtypes; 
luminal, HER2, basal-like, normal-breast-like, apocrine, interferon-related and claudin-low 
types [100]. Microarray studies have created gene expression signatures predictive of 
prognosis and treatment response, which have identified proliferation and hormone receptor 
genes to have the most impact on prediction [101]. 
Depending on pathology, receptor expression, age and tumour dissemination at time of 
diagnosis, different treatment options are available. In locally advanced and inflammatory 
cancers, neoadjuvant chemotherapy is administered before surgery [102]. When surgery is 
performed, partial or complete mastectomy is performed together with SN biopsy and 
axillary dissection when the SN is positive. This is followed by chemotherapy (if indicated) 
and irradiation. Standard treatment for ER and/or PR positive patients is ER antagonist 
Tamoxifen for five years following surgery [99]. Lately, targeted agents have also begun to 
be used in breast cancer treatment. Antibodies against HER2 (trastuzumab) have increased 
survival [103], VEGF antibodies (bevacizumab) are approved and increase progression-free 
but not overall survival [104], while antibodies and drugs targeting other proteins such as 
tyrosine kinases and PARP are in trials [105].  
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1.7 URINARY BLADDER CANCER 
Urinary bladder cancer is the fifth most common cancer in men worldwide, with a global 
yearly incidence of 380 000 new cases and 150 000 deaths in both genders [79]. The 
incidence in men is three times higher than in women. Smoking is the main environmental 
risk factor, thought to cause about half of all cases. Other environmental risk factors include 
polycyclic hydrocarbons, arsenic and chronic schisostomosis. In the Western world, >90% 
of bladder cancers are urothelial in origin [106].  
Urothelial bladder cancer is divided into two clinically and molecularly distinct subtypes, 
muscle-invasive (MIBC) and non-muscle-invasive (NMIBC) based on invasion into the 
detrusor musculature. NMIBC is treated with cystoscopic resection, with BCG upon 
relapse. Recurrence is common, but progression into invasive carcinoma occurs in only 20-
30%, and five-year survival is 90% [107]. MIBC, which makes up 20-25% of all newly-
discovered bladder malignancies, has a poor prognosis, with 5-year survival for stages T2-
T4 being around 50% with best treatment, consisting of radical cystectomy, 
lymphadenectomy and neoadjuvant chemotherapy [106, 108]. 
MIBC is highly genetically unstable, showing high rates of aneuploidy and heterogeneity 
[109]. Mutations in DNA maintenance and repair genes including MCM4, ERCC2, ATM 
and FANCA have been associated with MIBC, and chromosome 9 loss is common in both 
NMIBC and MIBC. Activating mutations in FGFR3 and overexpression of EGFR, as well 
as p53 mutations, are also common in MIBC [106]. 
MIBC is a relatively quickly metastasising malignancy. One of few larger autopsy studies 
found 69% of MIBC patients to have metastases, mainly to the liver and local lymph nodes. 
In the patient subset metastases, 90% had tumour cells in the lymph nodes, showing that 
MIBC spreads mainly through local lymph nodes. Metastasis frequency follows tumour 
stage, with 80% of T4 patients and 36% of T2 patients showing either regional or distant 
metastasis. [110]. 
 
1.8 PERSONALISED CANCER MEDICINE 
Starting with Paul Ehrlich's concept of the “magic bullet”, selectively targeting disease-
causing micro-organisms or cells with specific receptors while sparing other cells, 
personalised medicine as a theory has a long history. The development and subsequent 
clinical use of monoclonal antibodies towards growth factor receptors achieved the magic 
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bullet in oncology. However, the great redundancy in cell signalling pathways along with 
the heterogeneity of tumours means that targeted therapy alone is rarely curative. However, 
with recent advances in omics technologies, providing complete genomes, transcriptomes 
and proteomes for each patient, truly personalised cancer medicine is within reach. Through 
integrating deep knowledge of individual tumour signalling with known effects of the 
available array of targeted treatments, one can predict optimal treatment combinations for 
each patient [111].  
Personalised medicine aims to treat the right patient with the right combination of drugs at 
the right time to achieve maximum efficacy while minimising side-effects and resistance 
development. However, for this trivial definition to transfer to actual patient benefit a 
number of conditions must be fulfilled. Diagnostic modalities are necessary that have the 
capability to correctly predict prognosis, stratify patients to different treatments and 
monitor treatment response by re-applying tests between and after treatments to find 
surviving resistant clones. In addition, drugs need to specifically target the different 
pathways affected in cancer patients in such combinations that clones resistant to all drugs 
in the treatment combination have a very low risk of arising. Naturally, both diagnostics 
and treatments must be able to account for the massive inter- and intra-tumour 
heterogeneity [9]. 
 
1.8.1 Omics 
Omics refers to a number of technologies that are able to quantify and study the global 
expression patterns of biomolecules as opposed to single genes or proteins [112]. Omics 
approaches exist on all levels of cell signalling. Genomics and transcriptomics, greatly 
boosted through the arrival of next-generation sequencing, study of whole genomes and 
transcriptomes, as well as patterns of epigenetic modifications and non-coding RNAs. 
Several tumour types have had their entire genome sequenced, revealing previously 
unknown driver genes [113]. Mass-spectrometry (MS) based proteomics have reached a 
coverage of over 10 000 proteins, identifying new protein-coding loci through integration 
with known DNA sequences [114], and are also able to identigy post-translational 
modifications and protein-protein interactions. Metabolomics, studying small metabolic 
molecules through mass spectrometry and nuclear magnetic resonance spectroscopy, also 
has wide applications in cancer, such as exploring metabolic changes, drug mechanisms 
and toxicities [115]. 
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These technologies have been applied in many cancer settings, successfully creating 
expression signatures classifying cancers by sub-type and found hundreds of putative 
prognostic and treatment biomarkers on different biological scales. However, much fewer 
treatments targeting these genes and proteins have been approved and successfully used in 
the clinic. The main limitations lie in the validation pipeline. Model systems used to 
identify biomarker signatures often fail to accurately represent the cancer ecosystem; thus, 
experimental findings may not be transferrable to clinical use. Furthermore, biomarkers 
identified in a certain patient subset may not be applicable in those patients selected for 
clinical trials, typically suffering from advanced disease. The genetic instability and 
heterogeneity of these patients, coupled with the redundancy of cancer signalling pathways, 
means that drugs targeted against single biomarkers may not have any clinical effect 
because of the high resilience to selective pressures in advanced tumours displaying a wide 
range of sub-clones [116]. 
 
1.8.2 Targeted Treatments 
Small molecules targeting proteins specific to or overexpressed in cancer cells are a 
necessity if the biomarkers identified by omics technologies are to be exploited. Cancer-
specific proteins are better targets since drugs specific against these targets will not affect 
normal cells. There have been certain successes, including the tyrosine kinase inhibitor 
(TKI) imatinib which targets the BCR-ABL fusion protein in chronic myeloid leukaemia 
(CML) and has successfully increased survival in CML patients [117] and PARP inhibitors 
in BRCA-mutated cancers, which exploit the fact that only BRCA-mutated cells are 
sensitive to PARP inhibition because of their already defective DNA repair [118]. 
Approved targeted therapies against proteins amplified in cancer include trastuzumab in 
Her2-positive breast cancer [119] and both antibodies and kinase inhibitors against EGFR 
antibodies in a range of cancers, including lung, pancreas and head and neck [120, 121].  
However, resistance development is a problem, especially when only single targeted drugs 
are administered. Both in the case of TKIs [122] and antibodies [123], tumour 
heterogeneity greatly increases the risk that a subset of cells survive the treatment and 
expand, forming resistant clones. Resistance can either be intrinsic or acquired, and can be 
achieved through numerous mechanisms, including mutations in the target itself, activation 
of bypass pathways either through up-regulation of non-targeted kinases or re-wiring of 
downstream signalling, and disabling of apoptosis pathways. To overcome this problem, 
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combining multiple targeted treatments is an attractive option, which accounts for a larger 
part of tumour heterogeneity and diminishes the possibility of pathway re-wiring [124]. 
Examples include combining RAF inhibitors with MEK and PI3K inhibitors in melanoma, 
which limits the number of possible resistant growth signalling pathways [125]. 
 
1.8.3 Systems Medicine 
The availability of wide-spanning, high-resolution mapping of cancers from genome to 
metabolome has underlined the fact that cancer is a complex disease of disrupted signalling 
networks, that, due to intra-tumour heterogeneity, is highly resilient to perturbations. The 
limited success of targeted therapies underlines the fact that a reductionistic approach 
focusing on single oncogenic molecules is sub-optimal. Systems biology in cancer 
addresses this problem by studying cancer as a big signalling network, constructing 
mathematical models that can predict, in an unbiased manner, the properties of the entire 
network based on biomolecular data, and how external perturbations such as addition of 
drugs will impact this network [126]. 
The application of systems biology through integration of omics data with in silico 
modelling has already shown promise. Examples include the prediction and validation of 
PTEN levels as predictive of response to trastuzumab [127], modelling of glioma dynamics 
to improve radiotherapy scheduling [128] and integration of sequencing data with cellular 
responses to ligand stimulation in order to predict the impact of 23 targeted drugs on 
pathway signalling and outcome [129]. 
Systems biology is a necessary component for personalised medicine. Modelling integrated 
data on clinical outcomes, tumour characteristics and drug structure and mechanisms and 
applying machine learning algorithms, one arrives, in an unbiased manner, at predicted 
optimal treatment combinations for patients with defined signalling characteristics and 
dynamics [10]. This leads precisely to the goal of personalised medicine – the right 
treatment for the right patient at the right time (Fig. 11).  
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Figure 11. The systems biology approach integrates patient data down to genome level 
with known drug effects and clinical data, creating models which adapt diagnosis and 
treatment to individual patients. Reprinted by permission from Macmillan Publishers Ltd: 
Oncogene [126], copyright 2014. 
 
 
 
 
 
 
 
 
 
 26 
2 AIMS 
The general aim of this thesis was to evaluate and integrate different methods of analysing 
tumours, and apply them to personalisation of cancer medicine, focusing on predicting 
optimal treatment. The specific aims for each paper were: 
 
Paper I. Compare DNA and mRNA analysis for HPV sub-typing of cervical carcinoma in 
order to accurately differentiate between high- and low-risk patients. 
 
Paper II. Study HPV16 E2, E5 and E7 mRNA expression in relation to patient survival, 
HLA class I expression and CD8
+
 TIL infiltration in TSCC and BOTSCC to improve 
stratification of patients. 
 
Paper III. Identify optimal combinations of targeted drugs for different breast cancer 
signalling states through screening breast cancer cell lines with combinations of TGF-β, 
oestrogen, EGF and targeted drugs against these pathways. 
 
Paper IV. Evaluate whether proteomics on Tregs and Teffs in lymph nodes in individual 
MIBC patients combined with interactome modelling can predict targets for optimisation of 
immunotherapy. 
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3 MATERIALS AND METHODS 
3.1 PATIENTS AND SAMPLES (PAPER I, II, IV) 
Paper I included formalin-fixed paraffin-embedded (FFPE) tumour samples from 98 
primary cervical adenocarcinomas from patients who were diagnosed and underwent 
surgery at Karolinska University Hospital between 1992 and 2000. They were followed up 
until January 2007. 
Paper II included FFPE biopsies from 112 TSCC and 21 BOTSCC patients treated 
curatively between 2000 and 2011 at Karolinska University Hospital with follow-up data 
for at least three years. 
Paper IV included four MIBC patients who underwent radical cystectomy with 
lymphadenectomy at Umeå University Hospital, Gävle and Västerås hospitals. Prior to 
surgery, radioactive tracer (80 MBq technetium) was injected peritumorally. At surgery, 
sentinel nodes, defined by uptake of tracer measured by a hand-held Geiger counter, and 
control non-sentinel nodes were removed and put in RPMI on ice for transport to the 
laboratory. In addition, venous blood was taken and transported in heparin-containing tubes 
at room temperature. 
 
3.2 HPV GENOTYPING (PAPER I-II) 
In paper I, presence of HPV DNA was assessed by PCR with GP5+/6+ probes (targeting 
the L1 region). HPV typing was performed using single-strand conformational 
polymorphism (SSCP) and/or by direct DNA sequencing of the PCR products  from the L1 
region with previously developed assays [130]. Samples showing inconsistent results were 
analysed by reverse line blot [131]. 
For tumours included in paper II, presence of HPV DNA had for most samples been 
determined by PCR with GP5+/6+ and CPI/IIG probes, and genotyping for HPV16 by 
HPV16 E6-specific PCR, as described earlier [132]. Alternatively, mainly for samples after 
2008, the presence of HPV and genotyping was performed with a bead-based multiplex 
assay on a MagPix instrument, assaying for 24-27 HPV types [82]  
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3.3 RNA ANALYSIS (PAPER I, II, IV) 
In paper I, samples were analysed for E6/E7 mRNA from HPV types 16, 18, 31, 33 and 45 
through RT-NASBA (PreTect HPV-Proofer, NorChip AS). GAPDH was used as control 
for presence of mRNA in the samples.  
In paper II, a multiplex bead-based assay was developed to simultaneously analyse samples 
for several different HPV16 mRNA transcripts. After RNA extraction and treatment with 
DNAse, cDNA was synthesised using random primers. PCR was performed using primers 
for HPV16 E2, E5, E7, β-globin (control for DNA contamination) and U1A (control for 
cDNA synthesis from mRNA). PCR products were hybridised to sequence-specific probes 
coupled to fluorescent magnetic FlexMap beads. After incubation and washing, fluorescent 
streptavidin detection molecules were conjugated to the probe-bound amplicons. Presence 
of different amplicons was quantified in a MagPix instrument (Luminex Inc.) through 
illuminating the beads with a red laser for bead detection and a green laser for streptavidin 
detection. 
In paper IV, after RNA extraction and cDNA synthesis, RT-PCR was performed using 
probes against IL-16, with GAPDH used as housekeeping gene to normalise values. 
 
3.4 CELL CULTURE EXPERIMENTS (PAPER II-IV) 
In paper II, for validation of the multiplex HPV16 cDNA assay, the cervical cancer cell line 
Siha, tongue cancer cell lines UM-SCC-47 and UPCI-SCC-154 (all positive for HPV16) 
and the HPV-negative oral cancer cell line UM-SCC-14 were used. 
In paper III, MDA-MB-231 and MCF7 breast cancer cell lines were used. MDA-MB-231 is 
an oestrogen-negative, aggressive, mesenchymal-like cell line which forms metastases 
when injected into animals, while MCF7 is oestrogen-positive, slowly growing and forms 
tumours but not metastases in animals.  
The cells were seeded at 10 000 cells/well in a 96-well plate, cultured overnight where after 
they were treated with a total of 90 combinations of drugs and growth factors at different 
concentrations per cell line. 18 combinations of growth factors were used, with TGF-β1 at 
concentrations of 1 and 10 ng/ml, EGF at 50 and 100 ng/ml and 17-β-oestradiol at 10 μM. 
They were combined with either no drugs, 10 μM of the TGF-β kinase inhibitor SB431542, 
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1 μM of oestrogen antagonist Tamoxifen, 10 μM of EGFR TKI Iressa or all three drugs 
together. Impact on proliferation was determined by MTT assay after 48 hours of treatment. 
In paper IV, the urinary bladder cancer cell line 5637 was cultured for 36 hours, where after 
culture medium was aspirated and frozen at -80
o
C. For stimulation experiments, cells 
harvested from the patients were seeded at 300 000 cells/well in 200 μl total volume. Cells 
were either cultured in 150 μl tumour-derived supernatant and 50 μl basal culture medium 
or basal culture medium alone. Cells were harvested after 72 h for RNA isolation and PCR 
as described above. 
 
3.5 FLOW CYTOMETRY (PAPER IV) 
PBMC were isolated using Ficoll-Paque PLUS (Amersham Biosciences) density 
centrifugation gradient. From lymph nodes, leukocytes were extracted by gentle 
homogenization through a 40μm cell strainer. After extraction, CD4+ cells were isolated 
using EasySep Human CD4 positive selection kit (Stemcell Technologies).  
For flow cytometry, 500 000 cells/sample were first stained with LIVE/DEAD Fixable blue 
dead cell stain kit (Life technologies) followed by surface staining with fluorochrome-
conjugated antibodies. For intracellular antigens, surface staining was followed by fixation, 
permeabilisation and staining. Data was acquired on an LSRFortessa II (BD Biosciences). 
For sorting experiments, cells were surface stained, as described above, and sorted using 
the FACSAria flow cytometer (BD Biosystems). Sorted cells were immediately frozen in -
80
o
C. Data were analysed using FlowJO X 10.0.7r2 software (Tree Star, Ashland OR). Post 
sorting Treg and Teff purity was >90%. 
For intracellular cytokine staining, cells were suspended at a density of 2*10^6 cells/ml in 
Falcon 14 mL Polystyrene Round-Bottom Tubes (Becton Dickinson) in the prescence or 
absence of Phorbol Myristate Acetate (50 ng/ml) and Ionomycin (1 ug/ml). To inhibit 
cytokine secretion, Brefeldin A (GolgiPlug) was added 1 h after stimulation. Cells were 
harvested for FACS staining at 6 h after stimulation. 
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3.6 PROTEOMICS (PAPER IV) 
Frozen cell pellets were thawed on ice, sonicated and centrifuged to remove debris. 5 μg of 
protein/sample underwent denaturation, tryptic digestion and clean-up, as described in 
detail in the paper. The resulting mixture of tryptic peptides (1 μg/sample) was loaded onto 
a nano-Ultimate HPLC system with an acetonitrile gradient (Thermo Scientific) in-line 
coupled to a QExactive orbitrap mass spectrometer (Thermo Scientific). Mass spectra were 
searched against the SwissProt database using Mascot software (Matrix Science Ltd.). The 
false-discovery was limited at 1% over the entire peptide population. Quantitation, using 
Quanti software [133], was done through quantifying the ion current for each MS/MS 
spectrum. Only proteins with at least two identified peptides were quantified. A general 
overview of the workflow is found in figure 12. 
 
 
 
 
 
 
 
 
 
 
Figure 12. Overview of LC-MS/MS-based proteomics workflow. Reprinted from [134]. 
 
3.7 NETWORK ANALYSIS (PAPER IV) 
Identified proteins and their interaction partners, taken from validated human protein-
protein interactions in the SPIKE database [135], were used to construct protein interaction 
networks in Cytoscape [136]. Hierarchical clustering was performed with the clusterMaker 
plugin [137], network centralities (betweenness and node degree) were calculated with 
Centiscape [138] and the JEPETTO plugin [139] was used to identify enriched signalling 
pathways.  
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3.8 STATISTICS (PAPER I-IV) 
Paper I used standard measures of diagnostic accuracy such as sensitivity and specificity to 
compare the differences in performance between DNA- and RNA-based tests and Cox 
regression analysis to identify differences in survival between HPV mRNA-positive and 
negative patients.  
Paper II used the log-rank test to compare survival differences between groups. For 
progression-free survival, patients who died of causes other than cancer were censored. 
Patients were considered progression-free until relapse or death due to cancer. For relapse-
free survival, patients who were never disease-free, or for whom no relapse had been 
diagnosed at time of death, were censored in addition to those who died of other causes. 
Fisher's exact test was used to compare HLA class I expression between groups, as this had 
been coded as a binary variable. The numbers of CD8
+
 TILs were not normally distributed. 
For analysis, TIL numbers were therefore divided into four quartiles and group differences 
analysed using ordinal logistic regression from the MASS package in R.  
In paper III, Student's t-test was used for comparisons of proliferation between treatment 
conditions and for comparisons of tumour characteristics in the analysis of clinical data. 
In paper IV, the JEPETTO Cytoscape plugin [139] was used to test for enrichment of 
signalling pathways. The XD-score shows how close the input set of proteins is to a 
specific signalling pathway in the STRING molecular interaction network [140], and the q-
value is the significance value of Fisher's exact test corrected for multiple testing. 
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4 RESULTS AND DISCUSSION  
4.1 PAPER I 
Background and Aims  
In the last decades, there has been an increase in the incidence of cervical adenocarcinoma 
in several countries [141]. In the US, the incidence increased by 32% between 1973 and 
2007. Cervical adenocarcinoma has worse survival and a higher rate of metastasis than 
squamous cell carcinoma [142]. Arising high up in the endometrial canal, it is less likely to 
be detected with pap smear screening [143]. As the great majority of cervical 
adenocarcinomas are caused by hrHPV infection, hrHPV testing should be introduced in 
screening programs to identify these patients [144]. Since expression of E6 and E7 mRNA 
indicate an active HPV infection, the aim of this study was to evaluate whether detection of 
hrHPV E6/E7 mRNA through RT-NASBA was feasible in FFPE adenocarcinoma biopsies, 
and to compare the diagnostic performance of mRNA analysis with genotyping.  
Materials and Methods 
FFPE biopsies from 98 cervical adenocarcinomas were sectioned and underwent nucleic 
acid extraction. Presence of HPV DNA was assessed by PCR with GP5+/6+ probes 
targeting the L1 region. HPV genotyping was performed using SSCP and/or by direct DNA 
sequencing. RNA was analysed for E6/E7 mRNA from HPV types 16, 18, 31, 33 and 45 
through RT-NASBA (PreTect HPV-Proofer, NorChip AS). Samples showing inconsistent 
results between DNA and RNA analysis were analysed by reverse line blot [131]. 
Main Results 
- HPV DNA and RNA analysis agreed in 77% of cases for detection of HPV of any type. 
- All type mismatches that were re-analysed confirmed the HPV type as identified by RT-
NASBA. 
- The DNA assay reached a maximum sensitivity of 76.9% with a panel of four HPV types, 
while the RNA assay reached 80.8% sensitivity using three HPV types. 
- E6/E7 mRNA analysis through RT-NASBA is feasible in FFPE and more accurate than 
DNA genotyping for HPV classification. 
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Discussion 
Correct HPV classification is important not only for identification of cervical 
adenocarcinoma patients in a screening setting, but also for research. Since HPV DNA 
integration is seen during development of invasive cancer, HPV infections may be missed 
when analysing samples with probes for episomal DNA [145]. This study proved the 
feasibility of analysing HPV mRNA in stored FFPE biopsies. The PreTect RT-NASBA 
assay used in the present study has since then also been evaluated in other studies, showing 
higher specificity than DNA-based tests [146, 147].  
Weaknesses in this study were the small number of patients, the fact that not all samples 
yielded enough DNA for re-analysis and the absence of an uninfected control group, so that 
specificity values could be obtained.  
It should be noted that while presence of HPV DNA by itself is not proof of an HPV-driven 
carcinoma or pre-stages of cancer, the expression of HPV E6/E7 is a much stronger 
indication. Thus, when possible, E6/E7 RNA analysis of potentially HPV-driven tumours is 
preferable. Validation of an E6/E7 mRNA assay for cervical adenocarcinoma is important, 
since it helps to accurately identify patients in need of diagnostic biopsies, while also letting 
low-risk patients avoid invasive tests. 
 
4.2 PAPER II 
Background and Aims  
In the Western world, HPV-positive oropharyngeal cancer, where BOTSCC and TSCC 
account for the majority of cases, has been steadily increasing during the last decades. The 
prognosis is much better than for HPV-negative OSCC – 80% vs 40% 3-year disease-free 
survival. OSCC treatment has recently become more intensive, with chemoradiotherapy 
and anti-EGFR antibodies, leading to more side-effects. Since HPV-positive OSCC patients 
with absent HLA class I expression or a high number of CD8
+
 TILs have 95-100% survival 
with conventional radiotherapy alone, they can probably receive milder treatment, limiting 
side-effects [87]. The aim of this study was to see whether E2, the absence of which is 
associated with decreased survival in cervical cancer [148] and E5 expression, which has 
been shown to down-regulate MHC class I in cell lines [67] are associated with survival, 
CD8
+
 TIL counts or MHC class I expression in HPV-positive BOTSCC and TSCC, with 
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the goal of further improving identification of patients with good prognosis who can be 
selected for milder treatment. 
Materials and Methods 
FFPE biopsies from 112 TSCC and 21 BOTSCC patients, curatively treated with three 
years of follow-up, were analysed. All patients had previously been considered positive for 
HPV16 DNA, and stained for MHC class I (HC-10) expression and CD8
+
 TIL infiltration. 
RNA extraction with DNAse treatment was followed by cDNA synthesis and multiplex 
PCR with E2, E5, E7, U1A and β-globin probes – the latter two for quality control. RNA 
expression could successfully be analysed in 127 patients. Patients were defined as HPV16-
positive if E7 mRNA was expressed. 
Main Results 
- 10 HPV16 DNA-positive tumours did not express E7. Patients with E7-negative tumours 
had significantly worse survival and fewer CD8
+
 TILs than those with E7-expressing 
tumours, but E7 was not associated with HLA class I expression. 
- Neither E2 nor E5 mRNA expression were significantly associated with HLA class I 
expression or CD8
+
 TILs. 
- Absence of E2 expression was associated with significantly decreased disease- and 
progression-free survival. 
Discussion 
Absence of HPV E2 expression has previously been shown to be a poor prognostic factor 
for cervical cancer, but this study is the first to show that it is true in head and neck cancer 
as well. Disruption of the E2 gene is considered as an indication of HPV integration into the 
host genome, and has been show to increase transcription of E6 and E7 by removal of E2-
mediated inhibition of these genes [72]. The role of E5 in down-regulating MHC class I, 
seen in cell lines, was however not confirmed in our study. MHC class I down-regulation 
has been associated with poor prognosis in cervical cancer [149], while the opposite is true 
in HPV positive OSCC [91], and we showed that this paradoxical effect in OSCC is not 
dependent on E2, E5 or E7 expression.  
The fact that neither E2 nor E5 were associated with MHC class I expression or CD8
+
 TIL 
counts, both indicating good prognosis, while absence of E2 was associated with decreased 
disease-free survival means that E2 expression is an independent predictor of survival, 
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which can be combined with MHC class I expression and CD8
+
 TILs to increase the 
accuracy in stratifying patients with good prognosis to milder treatment. 
The correlation between E2 and clinical outcome was evaluated for 117 E7-expressing 
TSCC and BOTSCC patients. To be able to use HPV16 E2-expression as a prognostic 
marker in a clinical setting there is a need to confirm the data obtained in this study on a 
separate validation set. In addition, as mentioned above, E2 expression as often been 
regarded as an indication that the E2 is disrupted due to integration of the HPV genome into 
the cellular genome [150].  However, this is not necessarily so, as there may be deletions 
also in episomal HPV genomes [151] and E2 expression is not only repressed due to 
deletions also be repressed by methylation [152]. Notably, E2 methylation has been found 
to be highest in OSCC with integrated HPV genomes where the E2 gene is intact, 
intermediate in OSCC with episomal HPV and low when the HPV genome is integrated 
and E2 disrupted [152]. Further studies are needed to evaluate if the variation in E2 
expression observed in TSCC/BOTSCC in the present study is related to integration and/or 
methylation. Also, the mechanisms behind TIL infiltration and down-regulation of HLA 
class I were not explained by our study, and remain to be explored. 
 
4.3 PAPER III 
Background and Aims  
Tumour heterogeneity contributes to resistance development, which is why targeted 
treatments are rarely curative. Combinatorial treatments of several targeted drugs address 
this problem by simultaneously targeting multiple signalling pathways, decreasing the risk 
of resistance development through mutational re-wiring of signalling networks [10]. 
Treatment combinations may however interact unpredictably, producing unexpected 
toxicities [153] or having antagonistic effects [154]. Taking the complexity of tumour 
signalling networks, heterogeneity and cross-talk with the microenvironment into account 
also means that the effect of a combination will vary even within the same patient, 
depending on the signalling state of individual tumour sites.  
Oestrogen, EGF and TGF-β signalling are all driver pathways in breast carcinogenesis 
which cross-talk with each other [155-157]. ER and TGF-β signalling are mutually 
inhibitory. ER is mitogenic in early breast cancer, while TGF-β, growth-inhibitory in early 
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cancer, drives EMT and immunosuppression in later stages [158]. EGF contributes to 
hormone-independent growth, angiogenesis and invasion [159].  
The aim of this study was to screen breast cancer cells in different states of tumour 
development with different combinations of oestrogen, EGF and TGF-β and targeted 
treatments against these pathways in order to find response patterns predicting which 
combinations to use based on the tumour signalling state. 
Materials and Methods 
The ER-negative, metastatic, mesenchymal like MDA-MB-231 and ER-positive, epithelial, 
non-metastatic MCF7 breast cancer cell lines were treated with a total of 90 combinations 
of drugs and growth factors (EGF, 17-β-oestradiol, TGF-β1, SB431542, Tamoxifen, Iressa) 
for 48 hours. Proliferation was measured by MTT assay. Published transcriptome studies 
were re-analysed to validate cell line observations. 
Main Results 
- TGF-β1 inhibited proliferation of MDA-MB-231 cells treated with EGF and oestrogen. 
- Tamoxifen increased MDA-MB-231 proliferation, but addition of EGF and TGF-β to 
Tamoxifen decreased proliferation. 
- In MCF7 cells, combinations of Tamoxifen, EGF and oestradiol inhibited proliferation 
regardless of TGF-β. 
-  EGF together with Iressa had a stimulatory effect, blocked by TGFβ, in MDA-MB-231 
cells. 
- Combining all three drugs yielded the same patterns as not adding drugs, suggesting 
antagonistic interactions. 
Discussion 
The purpose of the study was to try out combinations of targeted drugs in an environment 
replicating tumour heterogeneity through usage of different breast cancer cell lines treated 
with growth factor combinations. Certain of our findings, notably the inhibitory 
combination of Tamoxifen, EGF and TGFβ, was in line with reports from earlier studies 
[160], confirming the validity of our screening approach. 
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The cross-talk between the TGFβ and ER signalling pathways was further investigated in a 
follow-up study, by proteome profiling of cells treated with SB431542 and Tamoxifen, and 
it was established that the pathways interact through BMP signalling (unpublished results).  
A notable weakness in this study is the absence of taking into account dynamic effects, with 
proliferation only studied at one time-point. Earlier experiments optimising the assay had 
showed that 48 h was a good compromise treatment time, especially since oestrogen 
signalling takes a long time to affect proliferation. Without automation, screenings such as 
in the present study have utility in generating hypotheses to be tested in-depth, but primary 
screening results are less useful.  
In the future, such screening approaches, creating a two-dimensional search space of drugs 
against signalling states with functional characteristics, such as proliferation or invasiveness 
as outputs, can be combined with in silico models in an iterative manner, with the model 
predicting useful combinations to be screened, and screening results used to improve the 
model [161]. 
 
4.4 PAPER IV 
Background and Aims  
MIBC is a disease with five-year survival around 50%, with somewhat better prognosis in 
responders to neoadjuvant cisplatin-containing chemotherapy, which, however, is 
associated with heavy side-effects. Targeted treatments have thus far been unsuccessful. 
The high rate of mutations [162], decreasing the efficacy of targeted treatments but 
increasing the chance of there being tumour-specific antigens, makes adoptive 
immunotherapy an attractive treatment option. However, immunosuppressive mechanisms 
must be overcome for this to be effective. MIBC is known to spread through the lymph 
nodes [110], where an immunosuppressive environment is established in a pre-metastatic 
before actual metastasis. The aim of this study was to perform proteome profiling of Tregs 
and Teffs in SN and nSN in order to see whether this method can be used to identify 
individual differences in T-cell signalling between patients and lymph nodes that can shed 
light on immunosuppressive mechanisms in the lymph nodes and be exploited to develop 
treatments that optimise the effects of adoptive T-cell transfer. 
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Materials and Methods 
Tregs and Teffs from peripheral blood, SN and nSN of two patients were sorted by FACS 
and analysed by LC-MS/MS-based proteomics. Network analysis was performed on protein 
interaction networks formed by the identified proteins. Validation experiments using FACS 
and RT-PCR were performed using cells from two other patients. 
Main Results 
- Tregs in SN displayed up-regulated growth and immune signalling pathways. 
- IL-16 is a central protein in SN-Treg signalling. 
- Secreted factors from the tumour down-regulate IL-16 mRNA expression. 
- Immunoproteomics is a useful tool to reveal important differences in signalling between 
patients and between lymph nodes in the same patient.  
Discussion 
The safety and feasibility of adoptive T-cell immunotherapy using expanded lymphocytes 
from sentinel nodes has been demonstrated in urinary bladder cancer, with a pilot study 
showing objective responses according to RECIST criteria followed by improved overall 
survival [163]. It has already been shown that the presence of Tregs in blood decreases the 
efficacy of adoptive T-cell transfer as cancer treatment [164], and the presence of Tregs 
among TILs in urinary bladder cancer has been associated with poor prognosis [165]. 
Considering that we propose to use TILs from the sentinel nodes for adoptive transfer, it is 
important to map the function of Tregs in these sites in order to find approaches to diminish 
their suppressive effects. 
This is, to our knowledge, the first study to profile the proteome of Tregs in lymph nodes. 
Considering that only two patients were profiled, the study is rather a proof of concept. 
Another weakness is the fact that the suppressive capabilities of the extracted Tregs could 
not be assessed, since all sorted cells were needed for proteomics and validation 
experiments.  
However, we did find SN-Treg growth and immune signalling to be up-regulated in both 
patients. Also, IL-16, which has previously been shown to be elevated in sera of cancer 
patients [166], was predicted to be central to SN-Treg signalling. We performed validation 
experiments in two other patients and showed that IL-16 is indeed expressed in Tregs, 
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something that has not been shown before. We also showed that it is more highly expressed 
in lymph node Tregs than in peripheral blood, and that co-culturing with tumour 
supernatant down-regulates IL-16 expression.  
This is an especially interesting finding, considering that IL-16 has a dual role. The secreted 
C-terminal part of the protein acts as a chemoattractant, inducing T-cell migration, while 
the N-terminal part is internalised and works as a cell cycle inhibitor in the nucleus [167].  
Further studies will focus on the mechanisms and impact of IL-16 down-regulation and on 
applying this immunoproteomic approach in a larger group of patients, trying to find and 
validate biomarkers which can be used as prognostic markers of immunotherapy success or 
as targets to decrease immunosuppression. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
In Paper I, we showed that mRNA detection through RT-NASBA is more accurate and 
sensitive than DNA genotyping for detecting and properly classifying HPV infection in 
cervical adenocarcinoma. This method has since been used successfully in other studies on 
cervical carcinoma. Seeing as RT-NASBA can be multiplexed, an obvious future direction 
is development of an assay which adds probes for other biomarkers of prognosis and 
treatment [168], improving diagnostic accuracy and treatment selection. 
Paper II applied HPV mRNA analysis to head and neck cancer, showing that absence of E2 
expression is an independent predictor of poor survival. This will be combined with data on 
HLA class I expression and CD8
+
 TIL counts, other independent predictors of survival, to 
select patients for milder treatment. The accuracy of such a three-variable model should be 
validated in a larger dataset. Other directions are continued studies on the role of E5 in 
relation to other biomarkers and clinical outcome in oropharyngeal cancer, which was not 
clarified by our study and the mechanisms behind HLA class I down-regulation. 
Paper III studied breast cancer through a systems medicine approach, where a search space 
of drugs and growth factors was created with proliferation as output. This project generated 
hypotheses, which are being followed up, that mechanistic studies of TGF-β-oestrogen 
cross-talk could provide new targets for treatment of breast cancer, and also showed how a 
simple screening approach can identify unexpectedly successful treatment combinations. 
Paper IV combined proteomics, systems biology and immunology for a clinical study of 
urinary bladder cancer. The identification of up-regulated growth and immune signalling in 
SN-Tregs, with IL-16 as a cytokine central to SN-Treg signalling was interesting, and 
further studies will focus on the mechanistic nature of IL-16 in Tregs, as well as on 
expanding this pilot study to a larger cohort, hopefully arriving at biomarkers helping to 
individually tailor adoptive immunotherapy. 
In conclusion, this thesis has applied a wide range of methodologies contributing to 
efficiently stratify patients and predict treatment combinations and target biomarkers in 
different cancer settings. Integration of data generated by these approaches with clinical 
outcomes and modelling will greatly advance the road towards personalised cancer 
medicine.  
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